LexaGene Holdings Inc. (LXXGF)
- GlobeNewswire
LexaGene Closes Multiple MiQLab Sales
BEVERLY, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce two purchase orders from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke. Dr. Jack Regan, LexaGene’s Founder and CEO commented, “I’m pleased to announce that we have closed additional MiQLab System sales to private hospitals. Veterinarian
- GlobeNewswire
LexaGene Intends to Pursue Full Panel Pathogen Testing through the FDA
BEVERLY, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it intends to pursue both 510k clearance and CLIA-waiver from the FDA to utilize the full potential of the MiQLab System™ for syndromic testing at the point of care. Syndromic testing allows medical providers to simultaneously test patient spec
- GlobeNewswire
Leading Veterinary Academic, Dr. Jane Sykes, Joins LexaGene Board of Directors
BEVERLY, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced Dr. Jane Sykes, BVSc(Hons), PhD, MBA, DipACVIM (Small Animal Internal Medicine) has joined the LexaGene Board of Directors. Dr. Sykes is the Executive Director of Innovation and Entrepreneurship, School of Veterinary Medicine at the University
